US-based biotechnology company Purigen Biosystems closed an $18.2m series A round on Tuesday backed by Roche Venture Fund, the corporate venturing unit of pharmaceutical firm Roche.
The round also featured Stanford University’s StartX Fund, which backs companies with a connection to the institution, 5AM Ventures and Western Investments Capital.
Founded in 2012, Purigen is developing a platform that purifies DNA or RNA samples to make cancer easier to detect through existing approaches. The technology is based on research by Juan…
